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To characterize patient-derived xenografts (PDXs)
for functional studies, we made whole-genome com-
parisons with originating breast cancers representa-
tive of the major intrinsic subtypes. Structural and
copy number aberrations were found to be retained
with high fidelity. However, at the single-nucleotide
level, variable numbers of PDX-specific somatic
events were documented, although they were only
rarely functionally significant. Variant allele fre-
quencies were often preserved in the PDXs,
demonstrating that clonal representation can be
transplantable. Estrogen-receptor-positive PDXs
were associated with ESR1 ligand-binding-domain
mutations, gene amplification, or an ESR1/YAP1
translocation. These events produced different
endocrine-therapy-response phenotypes in human,
cell line, and PDX endocrine-response studies.
Hence, deeply sequenced PDXmodels are an impor-1116 Cell Reports 4, 1116–1130, September 26, 2013 ª2013 The Autant resource for the search for genome-forward
treatment options and capture endocrine-drug-
resistance etiologies that are not observed in stan-
dard cell lines. The originating tumor genome
provides a benchmark for assessing genetic drift
and clonal representation after transplantation.
INTRODUCTION
Many stage 3 breast cancers and effectively all stage 4 breast
cancers are fatal, with annual worldwide deaths from the dis-
ease approaching one-half million (Youlden et al., 2012).
Large-scale partial and whole-genome sequencing (WGS) was
recently conducted on early-stage, treatment-naive breast can-
cer samples (Ellis and Perou, 2013). By contrast, the genomic
landscape of advanced and treatment-resistant breast cancer
is poorly documented. We therefore developed a panel of pa-
tient-derived xenografts (PDXs) from patients with poor-prog-
nosis, treatment-resistant disease for genomic and functional
studies, because early-passage PDX models reproduce gene
expression patterns observed in the originating human tumorsthors
and recapitulate the chemotherapy response (DeRose et al.,
2011; Fleming et al., 2010; Kabos et al., 2012; Marangoni
et al., 2007; Zhang et al., 2013). However, it has remained un-
clear to what extent PDX models accurately represent the
genomic characteristics of the originating tumor at a whole-
genome level. The value of the PDX approach in the setting of
estrogen-receptor-positive (ER+) breast cancer has also been
questioned because very few breast cancer PDXs expressing
ER have been reported.
WGS using massively parallel techniques is the gold standard
for comparing an originating tumor with a counterpart PDX
because partial-genome sequencing, which focuses on the cod-
ing sequence alone (i.e., exome sequencing), does not fully
document all mutations, particularly structural variations (SVs)
or other mutational events that occur in noncoding space (Ley
et al., 2008). Promisingly, WGS of a single example of a breast
cancer primary, a brain metastasis, and a PDX basal-like breast
cancer ‘‘trio’’ demonstrated that the PDX model efficiently cap-
tures almost all of the genome-wide somaticmutations observed
in the originating tumor, and displayed enrichment for mutations
that were present in the metastatic sample even though they
were derived from the primary tumor (Ding et al., 2010). Hetero-
geneity in mutation frequencies also has not been comparatively
evaluated for PDX models and originating tumors, so a custom-
ized capture approach (Welch et al., 2012) was used to generate
high depth at somatic variant positions genome wide, coupled
with statistical analyses for this comparison. RNA sequencing
(RNA-seq) was conducted to determine the expression level of
individual mutations and to confirm gene fusion events (Iyer
et al., 2011). Reverse phase protein array (RPPA) was employed
to determine whether protein and phosphoprotein expression
patterns were stable upon serial transplantation (Tabchy et al.,
2011). We also successfully developed multiple ER+ PDXs
from patients with endocrine-therapy-resistant disease, and
our genomic and functional analyses revealed mechanistic in-
sights into resistance that have not been achieved with conven-
tional cell line approaches.
RESULTS
Derivation and RNA/Protein Expression Patterns in
Xenografts from Advanced Stage Breast Cancer
Samples were obtained from 152 patients (Figure 1A), which
yielded 22 serially transplantable PDXs from 20 patients, for an
engraftment rate of 13.1%. These PDXs are referred to as
‘‘Washington University Human in Mouse’’ (WHIM) lines and
were mostly obtained from patients with advanced disease or
larger primary tumors that rapidly developed lethal metastasis
(Table S2A). Concordant ER andHER2 status was demonstrated
at themRNA level (Table 1), and PDX expression of ER andHER2
protein was confirmed by western blot (Figure S1). Mouse and
human centromere-specific fluorescent in situ hybridization
(FISH) assays were conducted to demonstrate that stromal ele-
ments were murine in origin, the malignant cells were human,
and there was no evidence for interspecies cellular fusion events
(Figures S2A–S2C). Agilent 44K Array-based mRNA expression
data were generated from the originating tumors and from
matched early- and late-passage PDX counterparts. We sub-Cell Rejected the matched pairs to unsupervised hierarchical clustering
after removing genes that were highly differentially expressed
between progenitor and PDX models (FDR = 0) to ensure that
this comparison was ‘‘tumor centric’’ and not confounded by dif-
ferences in the hybridization properties of mRNA arising from
human versus mouse stroma (Table S2B). In almost all cases,
the originating tumor and WHIM lines derived from the same in-
dividual clustered adjacently (Figure 1B). Each sample was also
classified into one of five intrinsic gene-expression subtypes;
lumenal A (dark blue), lumenal B (light blue), HER2-enriched
(pink), basal-like (red), and Claudin-low (yellow) using PAM50
(Parker et al., 2009) and the ‘‘Nine-Cell Line Claudin-low subtype
predictor’’ (Prat et al., 2010; Table 1; Figure 1B). The PDX lines
derived from ER+ clinical samples were all subtyped lumenal
by PAM50 in both the human and mouse samples, with the
exception of WHIM11, which was classified as HER2-E. Of
note, the human lumenal originating tumors expressed high
levels of cytokeratin 14 (CK14),CK5, and CK17mRNA, but there
was no evidence for expression of these CKs by the counterpart
lumenal PDX. To investigate this discordance, we conducted
immunohistochemistry for CK5 on the human lumenal tumor
progenitor samples (derived from cutaneous metastases). This
revealed normal-appearing CK5-positive epithelial cells
arranged in ducts ‘‘trapped’’ among CK5-negative malignant
lumenal epithelial cells, thereby ‘‘contaminating’’ the progenitor
tumor samples with basal epithelial keratins (Figure S2D). To
investigate the lumenal classification further, PDX mRNA was
also profiled on a 244K customized UNC Agilent chip (Cancer
Genome Atlas Network, 2012a) and the PDX data clustered
with clinical breast cancer samples profiled on the same plat-
form. In this analysis, all ER+ PDXs segregated with lumenal B
tumors (Figure S3). The WHIM12 line was derived from a meta-
plastic carcinoma and showed a near-perfect correlation with
the claudin-low signature (Figure S4). To address the stability
of PDXs at the level of protein and phosphoprotein expression,
multiple samples taken from the same passage and upon serial
passage were assayed by RPPAs (Tabchy et al., 2011). Data
from 110 antibodies for 68 samples harvested from 20 WHIM
lines were clustered with the data from 386 primary breast
cancers studied by The Cancer Genome Atlas (TCGA) research
network (Cancer Genome Atlas Network, 2012a; Table S2C). In
every case, the samples from each WHIM line clustered
adjacently, including the two double isolates (WHIM2 and
WHIM5, and WHIM20 and WHIM23; Figure S5). This suggests
that the intra-PDX proteomic heterogeneity was considerably
lower than the intertumoral heterogeneity in a large RPPA
data set and was relatively stable over time and passage.
The PDX samples were dispersed across the breast TCGA
data, indicating that they are representative of the heteroge-
neous biology of breast cancer. An analysis was conducted
to determine the relative rank of protein and phosphoprotein
levels for each WHIM tumor with respect to the ranges in
the TCGA data set (Table S2C). Here, the WHIM lines did
not contain any extreme data outliers with respect to the phos-
phoprotein levels documented in the TCGA data. Phosphoryla-
tion of the phosphatidylinositol-3-kinase/AKT pathway proteins
represented the highest-ranked pathway activation event
(Table 1).ports 4, 1116–1130, September 26, 2013 ª2013 The Authors 1117
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Genomic Fidelity of PDX Models
Using paired-end massively parallel sequencing, we sequenced
17 originating tumor, xenograft, and germ-line trio DNA samples
to R30-fold average whole-genome coverage. For 13 trios, we
subsequently validated each candidate mutation using solu-
tion-based hybridization capture followed by deep sequencing
of the originating tumor, the paired WHIM line, and the normal
DNA (for the somatic variants observed in WHIM4, WHIM24,
WHIM25, and WHIM26, further validation was not conducted;
see Table S2D for the coding region single-nucleotide variation
[SNV] observed in these examples). In the 13 cases subjected
to validation, a total of 59,189 genome-wide SNVs were
confirmed (Table S2E). Of these, 1,056 (1.8%) were nonsilent
protein coding mutations or in RNA genes (Table S2F). Across
all WHIM lines, there were 241 (range 0–77) out of a total of
58,814 validated genome-wide SNVs that were unique to the
originating tumor (0.4%). In contrast, a much higher number of
sites (5,450, range 29–1,564, 9.3%) were PDX specific (Table
S2G). Seventy-one mutations were detected in ‘‘significantly
mutated genes’’ (SMGs) as defined by TCGA data (Cancer
Genome Atlas Research Network, 2012b), lumenal tumors (Ellis
et al., 2012), or triple-negative tumors (Shah et al., 2012; Table
S2H). Each PDX harbored mutation(s) in at least one SMG
(WHIM6) and up to 12 SMGs (WHIM14). A small number of
potentially significant mutations were observed in the PDX but
not in the originating tumor (WNK2 in WHIM8, PIK3R4 and
KRAS in WHIM9, MAP4K2 in WHIM16, and CBLB in WHIM18).
Thirty-four PDX-specific missense mutations were identified as
potentially deleterious or functionally significant by a mutation
impact assessment algorithm (Xi et al., 2004), and all examples
contained at least one predicted deleterious PDX-specific
SNV, except for WHIM 2 (Table S2I). The PDXdata analysis pipe-
line removed sequence reads contributed by themurine genome,
thereby ‘‘computationally purifying’’ the human tumor DNA (Ding
et al., 2010). Biallelic deletions (e.g., in PTEN) were therefore re-
vealed with clarity in theWHIM analysis (Figure S6) and amplified
regions were often enhanced (Figures 2A, B, and S7–S9). Of the
5,336 copy-number variation (CNV) phenotypes that were de-
tected in the 13 cases analyzed, 5,036 (94.4%) had the same
call (amplified or deleted) in both the originating tumor and the
counterpart PDX line (Table S2L). Remarkably, all SVs (transloca-
tions, large deletions, and inversions) were preserved upon
transplantation, including regions characteristic of chromothrip-
sis (Stephens et al., 2011; Figures 2A, 2B, and S7).
Genomic Stability of PDX across Early and Late
Passages
Subsequent to our earlier report on comparative WGS of a pri-
mary tumor, brain metastasis, and primary-derived PDX trioFigure 1. Generation of a Biologically Diverse Panel of PDX Models fro
(A) Diagram indicating the genesis of the PDXmodels from patients with primary an
in mouse [Kuperwasser et al., 2004] and simple orthotopic).
(B) Unsupervised hierarchical clustering of samples using all genes of the micro
squares below the tree denote the subtype call of each sample. Red, basal-like; pi
low. Below the array tree and the subtype identification row, the heatmap of the
[CDH1], claudin 3 [CLDN3], CLDN4, and CLDN7) are shown. The stromal-related g
of 0% between 18 paired progenitor human tumors and xenografts. The comple
See also Figures S3 and S4.
Cell Re(Ding et al., 2010), a PDX model also was derived from the
patient’s brain metastasis (WHIM5), enabling a deep genomic
analysis of two xenografts from the samepatient. The vastmajor-
ity of the validated somatic SNVs and indels were shared by the
four genomes (n = 1,598) as well as seven translocations, 11 de-
letions, and four inversions. The breast primary tumor and brain
metastasis contained no single sample-unique SNV or SV (i.e.,
all of theSNVswerenoted inat least oneother sample; Figure 3A).
However, in every comparison, more SNVs were observed in the
tumor sample taken at a later time point when compared with a
sample taken at an earlier time point (whether a PDX sample
pair or a human sample pair). For example, in a comparison of
the two human specimens, 13 SNVs were unique to the primary
tumor, but 231 SNVswere unique to themetastasis. Additionally,
both WHIM lines harbored additional sample-unique noncoding
SNVs that become detectable after xenografting (39 in the case
of WHIM2 and 43 in the case of WHIM5; Figure 3B). Since
therapeutic experiments require extensive expansion of PDX
models, we also conducted a ‘‘late-exome’’ study to characterize
genomic drift in the WHIM2 genome, performing exome
sequencing on two separate passage eight tumor grafts (Fig-
ure 3C). This experiment detected 38 additional variants in both
specimens, although none of the SNVs were clearly damaging
mutations in cancer-associated genes (Table S2K).
The Genome-Wide Variant Allele Frequency Is a
Transplantable Phenotype
To compare mutant allele representation in the originating tumor
isolates versus their corresponding PDX models, we obtained
deep coverage through our capture-based validation approach
and then calculated the proportion of sequencing reads that
contained a mutant allele. This value was expressed as a per-
centage (variant allele frequency [VAF]) and analyzed by scatter-
plot (Figures 2C and 2D; see Figures S7–S9 for the remaining
examples). The genome-wide correlation coefficients across
the 13 tumor/PDX pairs varied from 0.32 (WHIM8) to 0.86
(WHIM5; Table S2L and Figures S7–S9). In the majority of cases,
there was statistical evidence for VAF stability genome wide,
with nine out of the 13 comparisons showing correlation coeffi-
cients above 0.65. For example, WHIM18 (R = 0.85) displayed
coding region (yellow) and noncoding region (blue) VAF stability,
including all six SMG mutations (Figure 2C). Eight other pairs
exhibited correlation coefficients above 0.65 (Table S1L), sug-
gesting that VAF stability was the rule, not the exception. Clearly,
differences in tumor purity biased the correlation, as the origi-
nating tumors were variably contaminated with DNA from normal
stromal elements, whereas the PDX had been computationally
purified. However, WHIM8 stood out from the other cases by ex-
hibiting a low correlation coefficient (0.26) and a relatively largem Patients with Advanced Breast Cancer
d advanced breast cancer, using two different implantation techniques (human
arrays except the stromal-related genes. The colors of the array tree and the
nk, HER2-enriched; dark blue, lumenal A; light blue, lumenal B; yellow, Claudin-
50 PAM50 genes as well as selected tight-junction-related genes (E-cadherin
enes were identified after a two-class paired SAMwas performed with an FDR
te list of up- and down-regulated genes can be found in Table S2B.
ports 4, 1116–1130, September 26, 2013 ª2013 The Authors 1119
T
a
b
le
1
.
S
u
m
m
a
ry
o
f
th
e
W
H
IM
L
in
e
B
io
m
a
rk
e
r
S
ta
tu
s
W
H
IM
N
u
m
b
e
r
In
tr
in
s
ic
S
u
b
ty
p
e
P
1
/L
a
te
W
H
IM
H
E
R
2
R
N
A
c
E
R
R
N
A
c
P
5
3
M
u
ta
ti
o
n
P
IK
3
C
A
M
u
ta
ti
o
n
E
S
R
1
M
u
ta
ti
o
n
T
ra
n
s
lo
c
a
ti
o
n
H
ig
h
e
s
t
R
a
n
k
e
d
h
u
m
a
n
p
a
s
s
a
g
e
h
u
m
a
n
/P
1
h
u
m
a
n
/P
1
h
u
m
a
n
/P
1
h
u
m
a
n
/P
1
a
m
p
lifi
c
a
ti
o
n
p
h
o
s
p
h
o
-p
ro
te
in
b
y
R
P
P
A
2
a
b
a
s
a
l
b
a
s
a
l
1
.3
3
.1
S
1
6
6
S
in
s
W
T
W
T
p
9
0
R
S
K
_
p
T
3
5
9
P
ri
m
a
ry
b
a
s
a
l
1
.0
1
.0
S
1
6
6
S
in
s
W
T
W
T
ra
n
k
=
2
5
.5
3
N
/A
H
e
r2
-E
N
/A
N
/A
N
/A
N
/A
W
T
S
rc
_
p
Y
5
2
7
P
ri
m
a
ry
H
e
r2
-E
1
.8
3
.8
W
T
W
T
W
T
ra
n
k
=
4
.0
4
b
a
s
a
l
b
a
s
a
l
5
.9
5
.7
R
1
7
5
H
W
T
W
T
p
2
7
_
p
T
1
9
8
S
k
in
m
e
t
b
a
s
a
l
2
.2
2
.2
R
1
7
5
H
W
T
W
T
ra
n
k
=
2
8
.7
5
a
b
a
s
a
l
b
a
s
a
l
3
.1
1
.1
S
1
6
6
S
in
s
W
T
W
T
p
9
0
R
S
K
_
p
T
3
5
9
B
ra
in
m
e
t
b
a
s
a
l
1
.8
1
.7
S
1
6
6
S
in
s
W
T
W
T
ra
n
k
=
6
2
.3
6
b
a
s
a
l
b
a
s
a
l
1
.5
3
.1
W
T
W
T
W
T
P
R
A
S
4
0
_
p
T
2
4
6
P
ri
m
a
ry
b
a
s
a
l
1
.2
3
.6
W
T
W
T
W
T
ra
n
k
=
5
9
.2
8
b
a
s
a
l
H
E
R
2
-E
8
.6
3
.6
Y
2
3
4
H
W
T
W
T
S
h
c
_
p
Y
3
1
7
S
k
in
m
e
t
H
E
R
2
-E
1
6
.8
4
.9
Y
2
3
4
H
W
T
W
T
ra
n
k
=
2
4
.7
9
L
u
m
A
L
u
m
B
1
.2
7
2
.2
W
T
H
1
0
4
7
R
W
T
A
k
t_
p
S
4
7
4
S
k
in
m
e
t
L
u
m
B
2
.1
3
6
5
.2
W
T
H
1
0
4
7
R
W
T
ra
n
k
=
2
5
.0
1
0
N
/A
b
a
s
a
l
N
/A
N
/A
N
/A
N
/A
W
T
N
/A
S
k
in
m
e
t
b
a
s
a
l
1
.6
2
.1
Y
2
2
0
C
W
T
W
T
1
1
H
E
R
2
-E
L
u
m
B
1
.6
3
1
.8
D
1
8
4
X
in
s
W
T
W
T
p
7
0
S
6
K
_
p
T
3
8
9
P
ri
m
a
ry
H
E
R
2
-E
1
.2
1
1
2
.1
D
1
8
4
X
in
s
W
T
W
T
ra
n
k
=
1
3
.3
1
2
C
L
D
N
lo
w
C
L
D
N
lo
w
5
.0
2
.4
R
2
4
8
Q
W
T
W
T
A
k
t_
p
T
3
0
8
P
ri
m
a
ry
C
L
D
N
lo
w
5
.0
1
.2
R
2
4
8
Q
W
T
W
T
ra
n
k
=
1
0
1
3
b
a
s
a
l
b
a
s
a
l
4
.8
2
.1
C
2
3
8
Y
W
T
W
T
S
rc
_
p
Y
5
2
7
S
k
in
m
e
t
b
a
s
a
l
1
.5
1
.0
C
2
3
8
Y
W
T
W
T
ra
n
k
=
1
4
.3
1
4
b
a
s
a
l
b
a
s
a
l
1
.0
5
.3
I1
9
5
T
W
T
W
T
N
/A
S
k
in
m
e
t
b
a
s
a
l
1
.3
1
.2
I1
9
5
T
W
T
W
T
1
6
L
u
m
B
L
u
m
A
2
.9
4
0
.1
R
2
4
8
W
H
1
0
4
7
R
A
M
P
4
E
-B
P
1
_
p
T
3
7
S
k
in
m
e
t
L
u
m
B
1
.2
1
7
1
.5
R
2
4
8
W
H
1
0
4
7
R
A
M
P
ra
n
k
=
1
3
.7
1
7
N
/A
b
a
s
a
l
N
/A
N
/A
N
/A
N
/A
W
T
P
K
C
-d
e
lt
a
_
p
S
6
6
4
P
ri
m
a
ry
b
a
s
a
l
2
2
.8
4
.1
W
T
W
T
W
T
ra
n
k
=
2
.5
1
8
L
u
m
A
L
u
m
B
3
.9
6
5
.5
W
T
E
5
4
5
K
E
S
R
1
Y
A
P
1
E
R
-a
lp
h
a
_
p
S
1
1
8
S
k
in
m
e
t
L
u
m
B
3
.1
1
9
.9
W
T
E
5
4
5
K
E
S
R
1
Y
A
P
1
ra
n
k
=
1
6
.5
2
0
L
u
m
B
L
u
m
A
3
.1
1
3
5
.2
C
1
8
2
X
E
5
4
2
K
Y
5
3
7
S
P
D
K
1
_
p
S
2
4
1
S
k
in
m
e
tb
L
u
m
B
5
.9
7
1
.6
C
1
8
2
X
E
5
4
2
K
Y
5
3
7
S
ra
n
k
=
5
7
.8
2
1
b
a
s
a
l
b
a
s
a
l
7
.5
6
.4
P
1
5
1
H
W
T
W
T
C
h
k
1
_
p
S
3
4
5
P
ri
m
a
ry
b
a
s
a
l
6
.8
1
.9
P
1
5
1
H
W
T
W
T
ra
n
k
=
1
6
.7
(C
o
n
ti
n
u
e
d
o
n
n
e
xt
p
a
g
e
)
1120 Cell Reports 4, 1116–1130, September 26, 2013 ª2013 The Authors
T
a
b
le
1
.
C
o
n
ti
n
u
e
d
2
2
b
a
s
a
l
b
a
s
a
l
2
.5
1
.2
C
2
7
5
F
W
T
W
T
E
G
F
R
_
p
Y
1
0
6
8
S
k
in
m
e
t
b
a
s
a
l
7
.7
2
.6
C
2
7
5
F
W
T
W
T
ra
n
k
=
2
4
.4
2
3
N
/A
L
u
m
A
N
/A
N
/A
N
/A
N
/A
N
/A
R
b
_
p
S
8
0
7
_
S
8
1
1
N
o
d
e
m
e
tb
L
u
m
B
1
.3
7
5
.8
C
1
8
2
X
E
5
4
2
K
Y
5
3
7
S
ra
n
k
=
2
7
.7
2
4
L
u
m
A
L
u
m
B
2
.1
1
8
.9
W
T
H
1
0
4
7
K
W
T
E
R
-a
lp
h
a
_
p
S
1
1
8
S
k
in
m
e
t
L
u
m
B
1
.3
7
1
9
.1
W
T
H
1
0
4
7
K
E
3
8
0
Q
ra
n
k
=
7
.0
2
5
b
a
s
a
l
b
a
s
a
l
3
.9
1
.1
R
2
7
3
H
W
T
W
T
M
A
P
K
_
p
T
2
0
2
_
Y
2
0
4
S
k
in
m
e
t
b
a
s
a
l
1
.8
1
.3
R
2
7
3
H
W
T
W
T
ra
n
k
=
2
0
.3
2
6
L
u
m
B
L
u
m
A
1
.9
5
9
.6
W
T
W
T
W
T
m
T
O
R
_
p
S
2
4
4
8
N
o
d
a
l
m
e
t
L
u
m
B
3
.5
5
2
.3
W
T
W
T
W
T
ra
n
k
=
2
.7
T
h
e
c
h
a
ra
c
te
ri
s
ti
c
s
o
f
2
2
W
H
IM
lin
e
s
d
is
c
u
s
s
e
d
in
th
e
te
x
t
a
re
s
u
m
m
a
ri
ze
d
,
in
c
lu
d
in
g
th
e
s
it
e
o
f
th
e
o
ri
g
in
a
ti
n
g
tu
m
o
r;
th
e
P
A
M
5
0
s
u
b
ty
p
e
o
f
th
e
o
ri
g
in
a
ti
n
g
tu
m
o
r
(‘‘
h
u
m
a
n
’’
)a
n
d
p
a
s
s
a
g
e
1
(P
1
)
a
n
d
a
la
te
r
p
a
s
s
a
g
e
(la
te
);
H
E
R
2
a
n
d
E
S
R
1
m
R
N
A
le
v
e
ls
n
o
rm
a
liz
e
d
to
W
H
IM
2
P
1
,
P
IK
3
C
A
,
T
P
5
3
,
a
n
d
E
S
R
1
m
u
ta
ti
o
n
s
ta
tu
s
a
n
d
p
h
o
s
p
h
o
p
ro
te
in
ra
n
k
in
g
b
a
s
e
d
o
n
W
H
IM
R
P
P
A
d
a
ta
w
it
h
in
th
e
c
o
n
te
x
t
o
f
3
8
6
T
C
G
A
b
re
a
s
t
tu
m
o
rs
(T
a
b
le
S
2
C
;
F
ig
u
re
S
3
).
S
e
e
a
ls
o
F
ig
u
re
s
S
5
a
n
d
S
1
2
.
W
T
,
w
ild
-t
y
p
e
.
a
W
H
IM
2
a
n
d
W
H
IM
5
fr
o
m
th
e
s
a
m
e
p
a
ti
e
n
t.
b
W
H
IM
2
0
a
n
d
W
H
IM
2
3
fr
o
m
th
e
s
a
m
e
p
a
ti
e
n
t.
c
R
e
fe
re
n
c
e
W
H
IM
2
e
a
rl
y
p
a
s
s
a
g
e
.
Cell Renumber of xenograft-specific mutations in the homozygous
range of 80% or higher (Figure 2D). This pattern suggests the
emergence of a clone that was below the detection limit in the
originating tumor sample but had become a significant contrib-
utor to the PDX mutational repertoire.
Most PDX-Specific Mutations Are Not Expressed
The RNA-seq approach (Cancer Genome Atlas Research
Network, 2012b) detected mRNA expression from 462 (44%)
of the 1,056 validated, nonsilent SNVs identified by DNA
sequencing of 13 PDX tumors (Table S2M). Expression was de-
tected for only 39 of the 69 SMG mutations. Of the PDX-unique
SMG mutations, only WNK2 in WHIM8, PIK3R4 and KRAS in
WHIM9, and MAP4K2 in WHIM16 were detectable in the RNA-
seq data. However, all TP53 mutations were expressed at high
levels (75%–100% of reads; Table S2H). The RNA-seq data
were also used to examine the expression of PDX-specific
missense mutations predicted to be functionally significant by
Polyphen (Xi et al., 2004). Of the 34 mutations in this class,
only 11 were expressed according to the RNA-seq reads (Table
S2I): Hist1H1E in WHIM6, ABCC1 in WHIM8, WDR81 in
WHIM13, MAP4K2 in WHIM16, ZNF687 in WHIM21, and
KRAS, SLC23A, LRRC58, MAPK9, KIF21B, and PIK3R4 in
WHIM9. Since MAP3K1 mutations have not been previously re-
ported in available cell lines, RNA-seq analysis was used to
confirm that a splice site mutation in WHIM20 indeed generated
a splice donor, leading to an out-of-frame MAP3K1 transcript
(Figure S10).
The Estradiol Response of ER+ PDX Mirrors the Clinical
Phenotype of the Originating Tumor
The estradiol dependence of each ER+ PDX was studied by
transplantation into oophorectomizedmicewith or without estra-
diol supplementation. Four lumenal PDX exhibited estradiol-
independent growth (Figures 4A, 4B, 4D, and 4E) consistent
with the fact these xenografted samples were accrued after
the development of aromatase inhibitor resistance (Table S2A).
WHIM24 was the only example that exhibited estradiol-depen-
dent growth (Figure 4F); the patient who contributed this sample
had a protracted clinical course and experienced a durable clin-
ical response to tamoxifen after xenograft sample accrual. The
growth ofWHIM16was delayed by estradiol (Figure 4C). Further-
more, established WHIM16 tumors exhibited marked regression
in response to estradiol exposure (Figure 4G), modeling the par-
adoxical estradiol treatment of advanced breast cancer, which
produced a modest response in the patient who contributed
this sample (Ellis et al., 2009). The patient who donated
WHIM18 had a particularly striking history of fulvestrant resis-
tance (progression within 1 month of therapy; Table S2A), and
WHIM18 proved to be just as fulvestrant unresponsive in the
PDX setting (Figure 4H).
ESR1 Translocation, Point Mutation, or Gene
Amplification in ER+ PDX Models
The RNA-seq data analysis identified five interchromosomal in-
frame gene fusion events (Figure S11), including a balanced
translocation between 6q and 11q in WHIM18 that created a
transcript encoding the 50 four exons of ESR1 (amino acidsports 4, 1116–1130, September 26, 2013 ª2013 The Authors 1121
A C
B D
Figure 2. Pairwise Genome-Wide VAF, CNV, and SV Analyses
(A and B) The circos plots for (A) WHIM18 and (B) WHIM8 show the closely
matched SVs and CNVs in the tumor of origin and the paired WHIM line. To
compare differences in mutant allele frequency between the originating tumor
and the PDX counterpart, the read counts for each mutant and wild-type allele
were expressed as a percentage of all reads at that position and analyzed by
scatterplot and simple correlation coefficient.
(C) WHIM18 has a high correlation coefficient (0.84) in both the coding region
(yellow) and noncoding region (blue). The VAF stability was maintained across
all six SMG mutations.
(D) WHIM8 represented the opposite extreme with a low correlation coefficient
(0.32) and a relatively large number of xenograft-specific mutations in the
homozygous range of 80% or higher. Related to this figure are analyses for the
other whole-genome sequenced originating tumor/PDX pairs that are dis-
played in Figures S7A–S9.
See also Figure S6.1–365), fused to the C terminus of YAP1 (amino acids 230–504;
Figure 5A). Western blots on WHIM18 extracts confirmed the
presence of an appropriately sized ESR1/YAP1 fusion protein
that was detected by an N-terminal ESR1 antibody and a
YAP1 antibody, but not by a C-terminal ESR1 antibody (Fig-
ure 5E). Gene amplification across the ESR1 promoter and
coding region was observed in WHIM16 (Figure 5B) and was
associated with high levels of ESR1 protein (Figure 5D). To quan-
tify and confirm the degree of amplification in WHIM16, we con-
ducted quantitative PCR (qPCR) of the promoter region and two1122 Cell Reports 4, 1116–1130, September 26, 2013 ª2013 The Auregions of the coding sequence of ESR1 (Figure 5C). In this
experiment, MCF7 cell DNA was used as a nonamplified ESR1
control, and, unexpectedly, MCF7 cells that had been subjected
to long-term estrogen deprivation (LTED) (Sanchez et al., 2011),
but not parental MCF7 cells, showed marked ESR1 gene ampli-
fication (Figure 5C) with associated increased expression levels
of ESR1 protein (Figure 5E). These data suggest that ESR1
amplification is an adaptation to estrogen deprivation in this
well-studied model. WHIM20 expressed an ESR1-Y537S point
mutation that was present in the majority of reads (96%) in the
RNA-seq data (Table S2M). WHIM24 harbored an ESR1-
E380Q mutation (Table S2D), which was not detected in the
originating tumor but was present in 42 of 42 reads in the PDX
(Figure S12). Low estradiol xenografting (i.e., no E2 supplemen-
tation) may therefore favor the growth of tumors with somatic
variants in ESR1, since four out of seven ER+ PDXs analyzed
by sequencing contained a mutation or a gene rearrangement.
Interestingly, in a recent study by Piccart et al. (2013), ESR1
sequencing of advanced breast cancer samples from a clinical
trial revealed both ESR1-Y537S and ESR1-E380Q. Piccart
et al.’s report, in combination with our observations, clearly de-
lineates a hot spot of ligand-binding-domain ESR1 mutations
in advanced breast cancer (Figure 5D) that complement the
initial example (Y537N) reported in the 1990s (Zhang et al., 1997).
ESR1/YAP1 and ESR1-Y537S Induce Estradiol-
Independent Growth
ESR1-Y537S and ESR1-Y537N are known to induce estradiol-
independent transcriptional activity (Weis et al., 1996; Zhang
et al., 1997). To compare the properties of ESR1 point mutations
affecting the Y537 residue with the ESR1/YAP1 fusion gene
product, MCF7 and T47D lines were engineered to overexpress
wild-type ESR1, ESR1YAP1, ESR1-Y537S, and ESR1-Y537N
proteins (YFP provided the control). Under low-estrogen condi-
tions, all three mutant ESR1 constructs increased proliferation
in T47D and MCF7 cells compared with the YFP control, and
the three mutant ESR1 constructs were all more active than
wild-type ESR1 (Figure 6A). In T47D cells, the proliferation of
cells harboring ESR1-Y537N or ESR1-Y537S was largely estra-
diol independent, although some estradiol responsiveness was
retained for ESR-Y537N in MCF7 cells. ESR1/YAP1 was as
active as the two point mutants in inducing estradiol-indepen-
dent growth, but E2 was able to further stimulate growth in
ESR1/YAP1-expressing cells in T47D cells. This indicates that
ESR1/YAP1 does not obviously function to inhibit the function
of endogenous ESR1 (i.e., it was not dominant negative). Fulves-
trant significantly inhibited the growth of cells expressing ESR1-
Y537S, ESR1-Y537N, and wild-type ESR1, and induced
downregulation of wild-type and mutant ER protein expression
(Figure S13). However, growth suppression was incomplete for
the two point mutants, suggesting partial resistance to fulves-
trant. Cells expressing the ESR1/YAP1 fusion were clearly
insensitive to fulvestrant and the fusion protein was not downre-
gulated, since the ligand-binding domain of ESR1 is absent from
this chimeric protein (Figure S13). Similar overall findings
regarding growth induction under low-estrogen conditions by
ESR1 mutants and the ESR1/YAP1 fusion were made in
MCF7 cells (Figure 6B). Of note, however, cells expressingthors
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Figure 3. Whole-Genome Comparisons of Breast Primary Tumor and Brain Metastasis with their Counterpart PDX Model Xenografts from
the Same Patient
(A) The majority of the validated somatic SNVs were shared by the breast primary tumor, brain metastasis, and xenografts (1,598). In addition, seven trans-
locations, 11 large deletions, and four inversions were present in all samples, without any SV detected or lost upon engraftment.
(B) The breast primary tumor and brain metastasis contained no sample-unique SNVs, i.e., all of the SNVs were noted in at least one other sample. However in
every comparison, more SNVs were observed in the later time sample than in the earlier sample. In a comparison of the two human specimens, 13 were unique to
the primary tumor and 231 were unique to the metastasis. Additionally, both WHIM lines harbored additional sample-unique noncoding SNVs (39 in the case of
WHIM2 and 43 in the case of WHIM5).
(C) Exome sequencing of two separate DNA samples isolated from WHIM2 passage 8, after expansion for therapeutic studies. Mutations in coding space have
accumulated, but a study of the 38 mutations observed in both samples suggests that most are passengers rather than biological drivers.
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Figure 4. Estradiol Dependency and Tumor Doubling Times for the ER+ WHIM Lines
(A and G) WHIM9 cells (A) or WHIM16 cells (G) were allowed to establish tumor nodules in ovariectomized nonobese diabetic (NOD)/severe combined immu-
nodeficiency (SCID) mice and then treated with or without 17b-estradiol pellets.
(B–F) Tumor cells were subcutaneously injected into ovariectomized NOD/SCID mice and then immediately treated with 17b-estradiol pellets or observed.
(H) Fragments of WHIM18 tumor tissue were subcutaneously engrafted into female CB.17 SCID mice. Tumor-bearing mice were treated in the presence or
absence of fulvestrant when tumor size reached 300 mm3. All data were analyzed in SAS using the PROC MIXED function.ESR1-Y537S grew poorly relative to cells expressing other ESR1
mutant constructs and exhibited signs of cell death (data not
shown). Gain-of-function ESR1 point mutants may therefore
require a cellular background that is tolerant of the extreme prop-
erties of these constitutively active ESR1mutants. In accord with
this hypothesis, ectopic expression levels for the Y537S mutant
were lower than wild-type ER in both T47D and MCF7 (Figures
6C and 6D), and were extremely low in WHIM20, which naturally
expresses the ESR1-Y537S mutant (Figure 5E). Lysates from
cells grown in charcoal-stripped serum (CSS) media were
analyzed for progesterone receptor (PR) and trefoil factor 1
(TFF1) expression by western blot. In both cell lines, the ESR1
point mutations strongly induced PR expression in a hormone-
independent fashion relative to wild-type ESR1 and YFP control
lines, whereas ESR1/YAP1 had a more modest effect. For TFF1,
the two ESR1 point mutants induced expression in MCF7 cells in1124 Cell Reports 4, 1116–1130, September 26, 2013 ª2013 The Aulow-estradiol conditions, but caused less induction in the T47D
cells. ESR1/YAP1 strongly induced TFF1 expression relative to
wild-type in both cell lines. In the WHIM tumors that expressed
these mutations naturally, high PR expression was associated
with the lines expressing the mutations or gene rearrangements
(WHIM16, WHIM18, WHIM20, and WHIM24). In contrast, WHIM
lines with a wild-type ESR1 locus (WHIM9 and WHIM11) but
estradiol-independent growth showed very low levels of PR
expression (Figure S14).
DISCUSSION
In this study, we assessed the degree to which breast cancer
PDX models are genomic replicas of human tumors based
on genome-wide analysis, including translocations, insertions,
deletions, pointmutations, and amplification events. The stabilitythors
AD E
B C
Figure 5. ESR1 Gene Rearrangements and Point Mutations in Lumenal PDX Models
(A) WHIM18 and the originating tumor harbored a balanced translocation between 6q and 11q in WHIM18 that created a fusion-transcript-defected mRNA-seq
that encodes the 50 four exons of ESR1 (amino acids 1–365, including the DNA-binding domain but not the steroid-binding domain) fused to the C terminus of
YAP1 (amino acids 230–504), thereby excluding the TEAD domain and the first WWmotif of YAP1, but retaining the second WWmotif, the SH3 domain, the YES
phosphorylation site, and the transactivation domain.
(B) WHIM16 and the originating tumor harbor amplification of the ESR1 gene that extends from the promoter region throughout the coding sequence that was
mapped using read counts obtained during WGS.
(C) qPCR on genomicDNA using three separate probeswas used to confirm gene amplification inWHIM16 cells. The negative control wasMCF7 cells. In a screen
for ESR1-gene-amplified cell lines, MCF7 cells that were adapted after LTED were found to have developed ESR1 gene amplification. qPCR results were
normalized relative to parental MCF7 (Par.). The positions of probes 1, 2, and 3 are displayed in (B). Error bars are ±1 SD of the mean relative quantification (RQ);
*p < 0.05, ** is p < 0.01.
(D) WHIM20 cells harbored and expressed a mutation in ESR1-Y537S, and WHIM24 harbors ESR1-E380Q (indicated in blue). The finding of ESR1-V537S and
ESR1-E380Q in these PDX lines complements a recent report on ESR1 sequencing of advanced disease samples in which multiple mutations in the AF2/ligand-
binding domain (in pink) were observed (Piccart et al., 2013; mutation positions from this report are indicated in red).
(E) Tumor lysates from six ESR1+ WHIM lines (WHIM9, WHIM11, WHIM16, WHIM18, WHIM20, and WHIM24) were analyzed by western blot using antibodies
targeting the N terminus or C terminus of ESR1 or the C terminus of YAP1. In parallel, lysates from three breast cancer cell lines (parental MCF7, LTEDMCF7, and
MDA-MB-231) were analyzed as controls. All blots were replicated four times. ESR1 intensity detected by the N-terminal ER antibody was quantified and
normalized against the actin level. For WHIM lines, the normalized ESR1 levels were averaged from four replicate blots and expressed as relative intensities using
WHIM9 as the internal reference (arbitrarily set at one). For cell lines, ESR1 levels were similarly normalized against actin and expressed as relative values using
parental MCF7 as the internal reference. Lysates from cell lines and WHIM tumors were analyzed in the same blot, but the images displayed reflect different
exposure times.
See also Figure S15.
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Figure 6. Point Mutations and a Transloca-
tion in ESR1 Induce Estradiol-Independent
Growth
(A and B) T47D(A) and MCF7 (B) cells stably
transduced with lentiviral vectors expressing the
YFP control gene (YFP), wild-type ESR1 (WT
ESR1), ESR1 point mutants (ESR1-Y537N and
ESR1-Y537S), and the ESR1-YAP1 fusion gene
(ESR1-YAP1) were grown in CSS medium for at
least 2 weeks. Cells were then plated in CSS
medium containing no supplemental estrogen
(E2), 10 nM estradiol (+E2), or medium without
estrogen +500 nM fulvestrant (+ Fulv), and growth
wasmeasured after 10 days by Alamar blue assay.
Mean results, with standard SEM as error bars, are
shown for four experiments (T47D) and three ex-
periments (MCF7), with each experiment con-
ducted in quadruplicate. Cell growth in each line
was normalized to baseline values obtained the
day after the cells were plated, prior to the begin-
ning of treatment. Expression of the ESR1 point
mutants and ESR1-YAP1 fusion significantly pro-
moted the growth of estrogen-deprived cells
compared with WT ESR1 or YFP control (*p < 0.05
indicates significant growth stimulation versus
YFP or WT ER). The effect of estradiol was then
assessed for each lentivirus construct (**p < 0.05
indicates a significant stimulatory effect for each
construct with and without estradiol). In T47D
cells, estradiol stimulated the growth of YFP,
ESR1-Y537S (minimally), and ESR1-YAP1, but not
WT-ESR1 or ESR1-Y537N. In contrast, in MCF7
cells, estradiol promoted the growth of WT-ESR1,
ESR1-Y537N, and to a much lesser extent ESR1-
YAP1, but not ESR1-Y537S. Treatment with
fulvestrant significantly inhibited estrogen-inde-
pendent growth of cells expressing WT ER and ER
point mutants (#p < 0.05), but not the ER-YAP1
fusion.
(C and D) T47D (C) and MCF7(D) cells were
cultured for 8 days in CSS medium, followed by
western blot for the expression of endogenous and exogenous ESR1 using an N-terminal antibody and two direct ESR1 downstream targets (progesterone
receptor [PR-A and PR-B] and TFF1) with an actin loading control. Due to the substantially lower basal TFF1 expression in T47D cells compared with MCF7 cells,
the T47D TFF1 blot was intentionally exposed for a longer time for visualization.
See also Figures S13 and S14.of SVs was striking, suggesting that these genomic features may
stabilize early in pathogenesis, perhaps during telomere crisis
(Chin et al., 2004). Regarding SNVs, almost all mutations de-
tected in the originating tumorwere present in the PDX, but a var-
iable number of SNVs were PDX unique (Table S2I). However,
RNA-seq data indicated that most PDX-unique SNVs have
expression levels below the detection limit and therefore may
be passengers. PDX-unique mutations could arise in the mouse
after xenografting or may represent a rare subclone that existed
below the detection limit in the originating tumor but increased
into the detectable range during growth in themouse. Deep anal-
ysis of a ‘‘quartet’’ of a primary and metastasis pair with their
counterpart PDX lines WHIM2 and WHIM5 suggests that xeno-
graft-specific mutations indeed arise over time. When we
compared samples taken at a later time point with those
obtained an earlier time point, whether in the human setting (pri-
mary tumor and brain metastasis) or xenograft setting, we found
that the later samples contained multiple SNVs (Figure 3). These1126 Cell Reports 4, 1116–1130, September 26, 2013 ª2013 The Aumutations may increase ‘‘tumor fitness’’ in the transplanted envi-
ronment or may just be passengers in a constantly mutating
tumor (most were in noncoding regions). PDX-specific SNVs
may simply arise from serial population reductions during
repeated xenografting events, which can select a passenger
mutation at random due to cell attrition during transplantation
(‘‘population bottlenecking’’; Gisselsson et al., 2010). This might
explain the accumulation of seemingly nonfunctional mutations
observed with late-passage exome sequencing (Table S2K).
However, selection by increasing tumor fitness is a more likely
explanation for cases in which the PDX-specific mutations
were detectable at the mRNA level and were functionally linked
to cancer biology, such as WNK2 in WHIM8 (Jun et al., 2009;
Moniz et al., 2007), PIK3R4 (Huang et al., 2011; Shull et al.,
2012) and KRAS (Santos et al., 1984) in WHIM9, MAP4K2 in
WHIM16 (Lau et al., 2012), and ESR1-E380Q in WHIM24.
Thus, we are not arguing that PDXs are perfect genomic replicas
of the originating tumors; rather, we suggest that tracking thethors
PDX genome, benchmarked against the originating tumor, is a
way to assess the ongoing genomic integrity of the model during
experimentation. This is something that has never been consid-
ered for conventional cell-line approaches, where the progenitor
tumor genome is rarely available and analysis of ongoing genetic
drift is not a routine aspect of experimental design.
An important issue that was not addressed by previous inves-
tigations is the effect of the xenografting process on the VAF,
since each mutation can either be present in the founder clone
(and therefore present in all cells) or arise later in a subclone
and therefore occur with a lower frequency because it is present
in only a subpopulation of cells. VAF analysis, perhaps surpris-
ingly, showed that the VAF for many mutations was preserved
in the PDX, even in the case of rare mutations. This implies
that clonal representation can be transplantable, i.e., different
clones maintain their relative prevalence in equilibrium. Since
clonal prevalence is maintained despite growth in an immuno-
compromised host, immunoediting (differential immune re-
sponses against particular mutant proteins) is an unlikely
explanation for relative clone abundance in this setting (DuPage
et al., 2012; Matsushita et al., 2012). Our findings are compatible
with other recent studies on the clonal diversity of epithelial
cancers, which showed that minor clones are carried at low fre-
quencies for many passages until a section event (e.g., thera-
peutic intervention or the process of adaption to growth in a
new organ) increases the minor mutation prevalence (Ding
et al., 2012; Kreso et al., 2013).
Genomic analysis of each ER+ PDX raised tumor-unique hy-
potheses to explain endocrine-therapy resistance, underscoring
the etiological heterogeneity of this common clinical problem.
The WHIM11 line was isolated from a patient with a fulminant
clinical course and little evidence for sensitivity to endocrine
therapy (Table S2A). Despite the patient’s ER+ HER2 status,
WHIM11 was classified as HER2-E by PAM50. This biomarker
pattern predicts poor responsiveness to aromatase inhibition
(Ellis et al., 2011). WHIM11 was a TP53 mutant and harbored a
biallelic deletion in PTEN (Figure S6). RPPA data confirmed
high levels of pS70S5K and 4EBP1 protein phosphorylation,
indicating phosphoinositol-3-kinase pathway activation (Fig-
ure S3), which has been implicated in endocrine-therapy resis-
tance (Sanchez et al., 2011). WHIM9 harbored monoallelic
expression of an R515I mutation in SMAD4 (Table S2M).
SMAD4mutations were recently associated with genome insta-
bility in head and neck cancer (Bornstein et al., 2009), which
could explain why this particular lumenal PDX had a high rate
of PDX-specific mutations, although which mutation caused
endocrine resistance in this line remains unclear.
WHIM16 exhibited paradoxical regression with estradiol,
which is an effective but nonintuitive late-line endocrine therapy
for some advanced ER+ breast cancers (Ellis et al., 2009). The
ESR1 amplification and high-level ESR1 protein expression in
WHIM16 therefore raise the hypothesis that ESR1 amplification
may be a predictive marker for responsiveness to estradiol ther-
apy in advanced disease. This suggestion is consistent with the
finding (Figures 5B and 5C) that MCF7 cells develop ESR1 gene
amplification after LTED in vitro, conditions under which estra-
diol is well known to induce apoptosis (Lewis et al., 2005;
Song et al., 2001). In T47D cells, overexpression of wild-typeCell ReESR1 gene/protein increased growth in low-estradiol conditions,
supporting the notion that by driving ESR1 overexpression,
ESR1 gene amplification promotes adaptive resistance to estro-
gen deprivation (Figure 6B). This hypothesis is also compatible
with clinical observations indicating that ESR1 amplification is
associated with poor clinical outcome (Ejlertsen et al., 2012;
Lin et al., 2013; Nielsen et al., 2011).
The ESR1-Y537S hormone-binding-domain mutation is
clearly a potent cause of aromatase-inhibitor resistance. Expres-
sion of ESR1-Y537S produced greater growth than wild-type
ESR1 under estrogen-deprived conditions and very strong in-
duction of PR in the absence of estradiol in both cell lines tested
(Figures 6C and 6D). Since ESR1-Y537S (or other mutations in
this region of ESR1) was not observed in >500 exome
sequencing experiments by the TCGA, it seems likely that muta-
tions in the hormone-binding domain largely occur as an adapta-
tion to endocrine treatment. Consistent with this conclusion,
an ESR1 mutation hotspot in the ligand-binding-domain/AF2
region was observed in metastatic samples from a clinical
trial for patients with nonsteroidal aromatase-inhibitor-resistant
advanced breast cancer (Piccart et al., 2013). Our in vitro data
indicate that ESR1-Y537S was responsive to fulvestrant, as pro-
tein expression was downregulated. However, suppression of
growth was incomplete, indicating partial resistance (Figures 6
and S13). The patient whose tumor harbored ESR1-Y537S
(WHIM20) experienced only 4 months of clinical benefit from ful-
vestrant, which is compatible with the hypothesis that ESR1-
Y537S-positive tumorsmay be less responsive to this commonly
used second-line endocrine intervention for advanced breast
cancer. WHIM24, a PDX that was estradiol dependent (Figure 4)
and associated with a tamoxifen clinical response (but resis-
tance to aromatase inhibition) harbored an ESR1-E380Q muta-
tion. This mutation has already been documented to be
associated with estradiol hypersensitivity, increased DNA bind-
ing, and estradiol-independent activity (Pakdel et al., 1993).
However, ESR1-E380Q was not detected in the relatively low-
coverage WGS analysis of the originating tumor, so the link
with the clinical phenotypes observed is uncertain (Figure S11).
The identification of the ESR1/YAP1 fusion gene in WHIM18
completes the mechanistic spectrum of gain-of-function muta-
tions in ESR1 associated with endocrine-resistant breast can-
cers. YAP1 plays a central role in organ size and tumorigenesis
through the Hippo pathway (Lin et al., 2013); however, the do-
mains that are responsible for most of these biological properties
are in the N terminus of YAP1 and therefore absent from the
fusion gene. Analysis of TCGA breast cancer RNA-seq data re-
vealed two other in-frame fusion genes that preserve at least
the first four exons of ESR1 (preserving DNA binding). In one
case, a fusion was detected with AKAP12, a putative tumor-
suppressor gene (Gelman, 2012), and in the second case it
was detected with POLH, a DNA polymerase associated with
xeroderma pigmentosum (Ortega-Recalde et al., 2013; Fig-
ure S15). These findings indicate that the ESR1/YAP1 transloca-
tion documented in WHIM18 is not a private event, but is a
member of a class of translocations that preserve the DNA-bind-
ing and AF1 domains of ESR1 with variable in-frame C-terminal
partners that replace the ligand-binding and AF2 domains.
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denominator for breast cancer is so large that even low percent-
ages of particular somatic events can represent clinically signif-
icant patient populations if the effect on the disease course is
dramatic (i.e., in this instance, intrinsic and universal endo-
crine-therapy resistance).
In conclusion, PDX models validated through comparative
whole-genome analysis against the originating tumor are a use-
ful starting point for studies of the molecular pharmacology of
advanced breast cancer. No actively growing cancer has a static
genome, and genetic drift though cell attrition is inherent in the
xenografting process. Furthermore, selection of mutations that
increase tumor fitness in the murine environment is to be ex-
pected. However, unlike conventional cell lines, PDX-specific
mutations can be monitored with reference to the genome of
the originating human tumor, establishing a tumor ‘‘pedigree’’
that can be checked before and after each functional or pharma-
cological experiment. This continuous genomic annotation
approach is illustrated by the late-passage exome sequencing
conducted in WHIM2 (Figure 3).
The identification of endocrine-resistance-associated ESR1
gene rearrangements and point mutations has deep implications
for the management of metastatic breast cancer. The choice of
endocrine therapy in an advanced-disease setting could be
based on the presence and class of ESR1 gene mutations and
rearrangements if more were known about the correlations
with outcomes. The detection of thesemutations in the xenograft
setting establishes the principle that the PDX approach captures
genomic events that have been understudied in the past
because they are not present in conventional ER+ cell lines
even when experimentally selected for endocrine drug resis-
tance in vitro. The availability of authentic PDX-based models
of endocrine-therapy-resistant lumenal breast cancer will facili-
tate the testing of therapeutic interventions and perhaps partic-
ularly those designed to more effectively target mutant forms
of ESR1.EXPERIMENTAL PROCEDURES
Generation and Analysis of PDX Breast Cancer Models
All human tissues for these experiments were processed in compliance
with NIH regulations and institutional guidelines, and approved by the
institutional review board at Washington University. All animal pro-
cedures were reviewed and approved by the institutional animal care
and use committee at Washington University in St. Louis. Detailed
methods are provided in Extended Experimental Procedures. PDX
models are available through the application to the Human and Mouse-
Linked Evaluation of Tumors core at http://digitalcommons.wustl.edu/
hamlet/.WGS and Capture Validation
Seventeen patients with blood, tumor, and xenograft were selected for
WGS. Detailed histories for these patients and xenografts are provided in
Table S2A. Libraries were prepared using unamplified genomic DNA from
blood (normal), tumor, and xenograft samples. Paired-end sequencing was
performed on the Illumina platform as previously described (Ellis et al., 2012;
Walter et al., 2012). Variant calling and validation of all mutations using
liquid-phase hybridization capture were performed as previously described
(Welch et al., 2012). All DNA have been deposited with dbGAP under acces-
sion number phs000611 (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
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mRNA-seq was performed as previously described (Cancer Genome Atlas
Research Network, 2012b). Reads were mapped using the MapSplice
algorithm (Wang et al., 2010). Expressed gene fusions were nominated using
ChimeraScan v0.4.3 (Iyer et al., 2011) with default parameters. Gene fusion
nominations were required to have at least two independent spanning junction
reads. Sequences will be made available upon application to CGHub. TCGA
mRNA-seq data can be accessed through the TCGA program (http://
cancergenome.nih.gov). All PDX mRNA-seq data have also been deposited
with dbGAP under accession number phs000611 (http://www.ncbi.nlm.nih.
gov/projects/gap/cgi-bin/study.cgi?study_id=phs000611.v1.p1).
DNA Microarray-Based Gene-Expression Analysis
Agilent’s 4x44K Whole Human Gene expression microarray processing, data
quality control and processing, and research use only PAM50 subtype
classification were previously described (Ellis et al., 2011). The stromal-related
genes were identified after a two-class paired significance analysis of
microarrays (SAM) with an FDR of 0% between 18 paired progenitor human
tumors and xenografts (Table S2B). The GEO accession number for the
chip-based gene expression data reported in this paper is GSM41685. PDX
tumors were also analyzed by 244K UNC customized Agilent chips for clus-
tering with data with unmatched primary tumors (GEO accession number
GSE46604).
Quantification of ESR1 Amplification
A real-time PCR system (Life Technologies) was run for ESR1 amplifications
using control genes FAM38B and ASXL2 as described previously (Reis-Filho
et al., 2008).
RPPA, In Vitro Growth Assays, Lentivirus Gene Transduction, and
Western Blots
Standard methods were used for RPPA (Tabchy et al., 2011); see Extended
Experimental Procedures for other standard protein-analysis approaches.
Statistical Methods
Hierarchical clustering was applied with a distance metric of one minus the
Pearson correlation coefficient and using the average linkage method. Clus-
tering results were visualized as dendrograms in heatmaps. Pearson and
Spearman rank-based correlation coefficients were separately calculated to
demonstrate VAF stability between a PDX and its patient origin.
ACCESSION NUMBERS
The dbGAP accession number for the DNA and PDX mRNA sequences re-
ported in this paper is phs000611. The GEO accession number for the gene-
expression data used in Figure 1B is GSM41685. PDX tumors were also
analyzed by 244K UNC customized Agilent chips for clustering with data
from primary tumors (GEO accession number GSE46604; Figure S3).
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